MX2015000485A - Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. - Google Patents

Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.

Info

Publication number
MX2015000485A
MX2015000485A MX2015000485A MX2015000485A MX2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A
Authority
MX
Mexico
Prior art keywords
fampridine
laquinimod
multiple sclerosis
combination
presenting
Prior art date
Application number
MX2015000485A
Other languages
English (en)
Spanish (es)
Inventor
Nora Tarcic
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015000485A publication Critical patent/MX2015000485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015000485A 2012-07-12 2013-07-11 Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. MX2015000485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12
PCT/US2013/050001 WO2014011827A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Publications (1)

Publication Number Publication Date
MX2015000485A true MX2015000485A (es) 2015-04-08

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000485A MX2015000485A (es) 2012-07-12 2013-07-11 Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.

Country Status (16)

Country Link
US (2) US20140017226A1 (OSRAM)
EP (1) EP2872217A4 (OSRAM)
JP (1) JP2015522077A (OSRAM)
KR (1) KR20150038072A (OSRAM)
CN (1) CN104582793A (OSRAM)
AR (1) AR091724A1 (OSRAM)
AU (1) AU2013290181A1 (OSRAM)
BR (1) BR112015000616A2 (OSRAM)
CA (1) CA2873229A1 (OSRAM)
EA (1) EA201590191A1 (OSRAM)
HK (1) HK1209672A1 (OSRAM)
IL (1) IL236230A0 (OSRAM)
MX (1) MX2015000485A (OSRAM)
TW (1) TW201408300A (OSRAM)
UY (1) UY34896A (OSRAM)
WO (1) WO2014011827A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CN101827522A (zh) * 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD

Also Published As

Publication number Publication date
HK1209672A1 (en) 2016-04-08
BR112015000616A2 (pt) 2017-06-27
JP2015522077A (ja) 2015-08-03
AU2013290181A1 (en) 2015-02-26
WO2014011827A1 (en) 2014-01-16
EP2872217A1 (en) 2015-05-20
TW201408300A (zh) 2014-03-01
US20160235735A1 (en) 2016-08-18
EP2872217A4 (en) 2016-03-16
CN104582793A (zh) 2015-04-29
KR20150038072A (ko) 2015-04-08
US20140017226A1 (en) 2014-01-16
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
AR091724A1 (es) 2015-02-25
CA2873229A1 (en) 2014-01-16
UY34896A (es) 2014-02-28

Similar Documents

Publication Publication Date Title
HK1205941A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
HK1198278A1 (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
IN2015DN03219A (OSRAM)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
NZ700759A (en) Combination therapy for treating cancer
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX355065B (es) Método y dispositivo para conmutación de cámaras.
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
HK1218251A1 (zh) 用拉喹莫德治疗多发性硬化症
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
IN2014DN09437A (OSRAM)
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2013038200A3 (en) Neurodevelopmental disorders
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
PH12014500252A1 (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
MX2016008214A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.
HK1223854A1 (zh) 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis